TisCRT-LAPC: A phase II study of tislelizumab combined with nab-paclitaxel and gemcitabine (AG) followed by consolidative radiotherapy in locally advanced pancreatic cancer (LAPC)

被引：0
|
作者：
Guo, Xi
Zhou, Yuhong
Ji, Yuan
Lou, Wenhui
Wu, Lili
Wang, Wenquan
机构：
[1] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Pathol, Shanghai, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Radiol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16350
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga
    Torregroza-Sanchez, Maria Patricia
    Bedoya-Apraez, Ivan Dario
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (02) : E16 - E18
  • [2] Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).
    Hammel, Pascal
    Lacy, Jill
    Portales, Fabienne
    Sobrero, Alberto F.
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Mozo, Manzano
    Terrebonne, Eric
    Dowden, Scot D.
    Li, Jack Shiansong
    Ong, Teng Jin
    Nydam, Thom
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] Gemcitabine (G) plus nab-paclitaxel (nab-P) plus chemoradiation (CRT) in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga Olanrele
    Bedoya, Ivan Dario
    Mierzwa, Michelle Lynn
    Torregroza, Maria Patricia
    Dwivedi, Alok Kumar
    Wang, Jiang
    Smith, Milton T.
    Schmulewitz, Nathan
    Kucera, Stephen
    Choe, Kyuran Ann
    Ristagno, Ross
    Rudich, Steven
    Sussman, Jeffrey J.
    Ahmad, Syed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] International phase II trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients with locally advanced pancreatic cancer (LAPC): LAPACT
    Philip, P.
    Kayitalire, L.
    Nydam, T.
    Penenberg, D.
    Hammel, P.
    ANNALS OF ONCOLOGY, 2015, 26
  • [5] Sequential neoadjuvant chemotherpy with nab-paclitaxel plus gemcitabine and FOLFIRINOX in locally advanced pancreatic cancer (LAPC): A PILOT study.
    Kunzmann, Volker
    Hartlapp, Ingo
    Scheurlen, Michael
    Einsele, Hermann
    Mueller, Justus
    Kenn, Werner
    Steger, Ulrich
    Germer, Christoph T.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Phase I study of chemoradiation therapy (nab-paclitaxel/Gemcitabine) in 15 patients with unresectable locally advanced pancreatic cancer (UR-LAPC).
    Sueyoshi, Hironari
    Ioka, Tatsuya
    Tamura, Takeshi
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Ohkawa, Kazuyoshi
    Takahashi, Hidenori
    Teshima, Teruki
    Katayama, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [7] Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).
    Lacy, Jill
    Portales, Fabienne
    Hammel, Pascal
    Cid, Roberto A. Pazo
    Mozo, Jose Luis Manzano
    Kim, Edward Jae-hoon
    Dowden, Scot D.
    Borg, Christophe
    Sastre, Javier
    Bathini, Venu Gopal
    Terrebonne, Eric
    Lopez-Trabada, Daniel
    Rivera, Fernando
    Asselah, Jamil
    Damiani, Azzurra
    Hwang, Jimmy J.
    Ong, Teng Jin
    Nydam, Thom
    Li, Jack Shiansong
    Philip, Philip Agop
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [8] Neoadjuvant nab-paclitaxel and gemcitabine (AG) in borderline resectable (BR) or unresectable (UR) locally advanced pancreatic adenocarcinoma (LAPC) in patients ineligible for FOLFIRINOX
    Peterson, Shawn
    Loaiza-Bonilla, Arturo
    Ben-Josef, Edgar
    Drebin, Jeffrey A.
    Westendorf-Overley, Colleen
    Anthony, Lowell Brian
    DeSimone, Philip A.
    Goel, Gaurav
    Kudrimoti, Mahesh R.
    Dineen, Sean Patrick
    Tzeng, Ching-Wei David
    Hosein, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [9] LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).
    Philip, Philip Agop
    Lacy, Jill
    Dowden, Scot D.
    Sastre, Javier
    Bathini, Venu Gopal
    Cardin, Dana Backlund
    Ma, Wen Wee
    Sobrero, Alberto F.
    Koski, Sheryl L.
    Borg, Christophe
    Tonini, Giuseppe
    Rivera, Fernando
    Hwang, Jimmy J.
    Knoble, Jeanna L.
    Al Baghdadi, Tareq
    Saif, Wasif M.
    Meiri, Eyal
    Kayitalire, Louis
    Li, Jack
    Hammel, Pascal
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [10] PANOVA-3: A phase III study of TTFields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC)
    Weinberg, Uri
    Farber, Ori
    Giladi, Moshe
    Bomzon, Zeev
    Lavy-Shahaf, Gitit
    Kirson, Eilon D.
    CANCER RESEARCH, 2018, 78 (13)
12345